Cadila Healthcare has informed that it has enclosed a copy of press release dated November 3, 2020 titled ‘Zydus announces IND filing of ZYIL1, a novel oral small molecule NLRP3 inflammasome inhibitor’. The contents of the press release give full details. Bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.
The above information is a part of company’s filings submitted to BSE.